About Glaukos
Glaukos ranks #19 in the Wall Street Journal's Top 50 Venture-Funded Companies more
A New Perspective
"Innovation and scientific integrity are the cornerstones of Glaukos Corporation. We are creating a portfolio of micro-bypass devices that are validated by extensive clinical, in vitro, and fluid mechanics research. We have conducted the first-ever landmark, randomized, concurrent control, US registration study for a Class III glaucoma device. We intend to bring innovative technology to the glaucoma market that will significantly advance patient care."
Thomas W. Burns
President and CEO, Director
About Glaukos
Mission Statement
Glaukos® is creating a new class of micro-bypass therapies to achieve sustainable target intraocular pressures through the restoration of physiologic outflow, reduce the challenges and risks of glaucoma management associated with traditional therapies, and aid in the preservation of vision.
Transforming Open-Angle Glaucoma Management
Founded in 2001 and headquartered in Orange County, California, Glaukos Corporation is an ophthalmic medical device company that is committed to transforming the management of open-angle glaucoma. The company is well capitalized to develop and commercialize innovative treatment technologies for glaucoma specialists and general, comprehensive ophthalmic surgeons. Through rigorous scientific and clinical research, Glaukos is developing a portfolio of minimally invasive micro-bypass stents to improve upon the safety and efficacy outcomes of surgical implant procedures.
